Healthcare provider profile · identity verified

Fhamida Khan, MD

Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MA · NPI 1013575026

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Fhamida Khan, MD received $16.53 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$16.53

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$16.53	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$16.53	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$16.53	1	2025
Source payment records 2025-04-14 · Lilly USA, LLC · $16.53 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$16.53	1	2025
Source payment records 2025-04-14 · Lilly USA, LLC · $16.53 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	115	23
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	54	17

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	615	182
Amlodipine Besylate	Amlodipine Besylate	405	131
Lisinopril	Lisinopril	385	111
Levothyroxine Sodium	Levothyroxine Sodium	303	74
Losartan Potassium	Losartan Potassium	278	80
Pantoprazole Sodium	Pantoprazole Sodium	270	97
Gabapentin	Gabapentin	218	61
Omeprazole	Omeprazole	212	77
Metformin Hcl	Metformin Hcl	182	51
Albuterol Sulfate Hfa	Albuterol Sulfate	164	67
Diclofenac Sodium	Diclofenac Sodium	158	76
Eliquis	Apixaban	158	36
Metoprolol Succinate	Metoprolol Succinate	156	47
Simvastatin	Simvastatin	150	40
Rosuvastatin Calcium	Rosuvastatin Calcium	135	33
Furosemide	Furosemide	127	38
Alendronate Sodium	Alendronate Sodium	122	32
Jardiance	Empagliflozin	115	23
Metformin Hcl Er	Metformin Hcl	114	39
Fluticasone Propionate	Fluticasone Propionate	113	47
Montelukast Sodium	Montelukast Sodium	113	31
Metoprolol Tartrate	Metoprolol Tartrate	102	29
Tamsulosin Hcl	Tamsulosin Hcl	102	21
Hydrochlorothiazide	Hydrochlorothiazide	99	34
Pravastatin Sodium	Pravastatin Sodium	87	24
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	85	42
Carvedilol	Carvedilol	76	20
Ozempic	Semaglutide	75	14
Famotidine	Famotidine	73	29
Sertraline Hcl	Sertraline Hcl	71	25
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	68	17
Meclizine Hcl	Meclizine Hcl	68	31
Glipizide Er	Glipizide	67	20
Hydroxyzine Hcl	Hydroxyzine Hcl	66	27
Januvia	Sitagliptin Phosphate	62	14
Mirtazapine	Mirtazapine	62	15
Trazodone Hcl	Trazodone Hcl	59	20
Glipizide	Glipizide	57	15
Trulicity	Dulaglutide	54	17
Clotrimazole	Clotrimazole	51	27
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	51	suppressed
Valsartan	Valsartan	49	12
Meloxicam	Meloxicam	44	18
Nifedipine Er	Nifedipine	44	11
Duloxetine Hcl	Duloxetine Hcl	43	15
Fenofibrate	Fenofibrate	41	suppressed
Ezetimibe	Ezetimibe	40	15
Atenolol	Atenolol	39	suppressed
Hydralazine Hcl	Hydralazine Hcl	39	suppressed
Spironolactone	Spironolactone	39	13
Ventolin Hfa	Albuterol Sulfate	39	12
Allopurinol	Allopurinol	36	suppressed
Naproxen	Naproxen	35	24
Chlorthalidone	Chlorthalidone	34	suppressed
Ketoconazole	Ketoconazole	34	14
Ondansetron Hcl	Ondansetron Hcl	34	17
Desmopressin Acetate	Desmopressin Acetate	33	suppressed
Finasteride	Finasteride	33	suppressed
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	11
Donepezil Hcl	Donepezil Hcl	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	28	11
Dicyclomine Hcl	Dicyclomine Hcl	28	16
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Memantine Hcl	Memantine Hcl	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	25	18
Ibuprofen	Ibuprofen	25	21
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Indapamide	Indapamide	22	suppressed
Enalapril Maleate	Enalapril Maleate	19	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	19	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	17
Celecoxib	Celecoxib	17	suppressed
Klor-Con M20	Potassium Chloride	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Levofloxacin	Levofloxacin	15	13
Prednisone	Prednisone	15	13
Topiramate	Topiramate	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Glimepiride	Glimepiride	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	13
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Labetalol Hcl	Labetalol Hcl	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Nystatin	Nystatin	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$16.53 · 1 records	Lilly USA, LLC	MOUNJARO, ZEPBOUND	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error